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The effect of short-term prostacyclin (PGI,) administration 
on the incidence of restenosis after coronary angioplasty 
was studied in a prospective single-blind randomized trial 
of 286 patients. Of the 270 patients in whom dilation was 
successful, 134 received prostacyclin and 136 received 
placebo. Intracoronary prostacyclin was administered be- 
fore and after dilation and then intravenously for 48 h. The 
control group received intracoronary placebo infusions 
before and after dilation. All patients received aspirin and 
dipyridamole before and after angioplasty, at least until 
follow-up angiography. 
Follow-up angiograms were obtained in 93% of patients 
in whom angioplasty was successful. Restenosis of one or 
Coronary artery restenosis after successful percutaneous 
transluminal coronary angioplasty occurs in 17% to 45% of 
patients (I). Attempts to reduce the incidence of restenosis 
by administration of drugs such as warfarin (2), calcium 
channel blockers (3.41, aspirin (5) and ticlopidine (6) have 
been unsuccessful. However, two studies (7,8) reported a 
lower incidence of restenosis with omega-3 fatty acid admin- 
istration, and a preliminary report (9) suggested that treat- 
ment with the prostacyclin analog Ciprostene (epoprostenol 
sodium) resulted in a trend to fewer instances of restenosis. 
Although the mechanism of restenosis is not completely 
understood, platelet deposition and degranulation are con- 
sidered to play a pivotal role in acute reclosure and probably 
contribute to late restenosis as well (10). Platelets adhere to 
the endothelium early after it is traumatized by balloon 
inflation (I l-13). This injury might further augment platelet 
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more lesions was present in 34 patients (27%) who were 
given prostacyclin compared with 40 patients (32%) in the 
control group (p = NS). Acute vessel closure and ventric- 
ular tachyarrhythmias were more common in the control 
group than in the patients who received prostacyclin (acute 
vessel closure occurred in 14 [10.3%] of 136 versus 4 
[3.0%] of 134, respectively, p < 0.01; ventricular tachyar- 
rhythmias occurred in 5 [3.4%] of 147 versus 0 of 139 
respectively, p < 0.05). 
Short-term administration of prostacyclin did not sig- 
nificantly lower the risk of restenosis after coronary angio- 
plasty. 
(J Am Co11 Cardiol 1990;15:691-7) 
aggregation by interfering with local production of prostacy- 
clin (PGI,). The thrombosis that results (14.151, as well as 
the subsequent proliferative and inflammatory responses, 
may lead to stenosis or obliteration of the lumen. Aspirin, 
which inhibits the production of thromboxane (161, is com- 
monly used in an attempt to prevent early reclosure and 
restenosis. However, it also inhibits endothelial production 
of prostacyclin. which has potent antiplatelet and vasodilat- 
ing properties ( 17, IS). 
We therefore hypothesized that optimal antiplatelet and 
vascular effects could be achieved by the administration of 
prostacyclin in addition to aspirin and dipyridamole, a 
hypothesis consistent with the positive findings of the 
previously mentioned studies of omega-3 fatty acid and 
ciprostene (7-9). Accordingly. we conducted a prospective 
randomized clinical trial to determine if short-term intracor- 
onary and intravenous administration of prostacyclin would 
reduce the incidence of restenosis after angioplasty. 
Methods 
Patient selection. Between June 1984 and September 
1985. 286 patients who were referred for coronary angio- 
plasty were enrolled in the study. The protocol was ap- 
proved by the Conjoint Medical Ethics Committee of the 
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University of Calgary and the Foothills Hospital and the 
Research and Development Committee at the Holy Cross 
Hospital. All patients gave written informed consent. 
Exclusion criteria included age ~18 or >75 years, men- 
struating women, uncontrolled hypertension or diabetes, 
history of stroke or recent (<3 months) gastrointestinal 
bleeding, previous angioplasty in the artery to be dilated, 
myocardial infarction within the previous month or pro- 
longed chest pain in the preceding 24 h. Patients were also 
excluded if they had been treated with a thrombolytic agent 
within 3 months or had participated in a drug trial within 9 
drug half-lives. Coronary artery anatomy and severity of 
disease did not influence enrollment. 
Study protocol. Patients were stratified according to 
whether single or multivessel dilations were to be performed 
and were randomized to receive either prostacyclin (Group 
A) or placebo (Group B). Immediate and noticeable facial 
flushing in Group A precluded effective double-blinding in 
this study. Patients did not know the treatment they re- 
ceived. Because the prime study end point was based on a 
blinded angiographic interpretation, the single-blind study 
design was believed to carry a low risk of bias. All patients 
received aspirin (325 mg) and dipyridamole (75 mg) three 
times daily (19,20), beginning the evening before angioplasty 
and continuing at least until follow-up angiography. 
Immediately before angioplasty, all patients received 
sublingual nifedipine (10 mg) and nitroglycerin (0.3 mg), 
intravenous heparin (10,000 IU) and intracoronary nitroglyc- 
erin (200 pg). After selective coronary angiography, patients 
in Group A received an intracoronary infusion of prostacy- 
clin (Upjohn Company of Canada) at a rate of 0.05 @kg per 
min, which was increased to 7.0 &kg per min over 5 min 
and then continued for an additional 10 min (21,22). Patients 
in Group B were given prostacyclin diluent at an identical 
infusion rate and for the same period of time. When both the 
left and right coronary arteries were to be dilated, the total 
infusion dose and time were divided equally between both 
vessels. 
Angioplasty was subsequently performed using a steer- 
able angioplasty system (U.S.C.1.X R. Bard Inc.). When 
two or more lesions were to be dilated, the “culprit” lesion 
was prospectively identified and angioplasty of that lesion 
was attempted first. The procedure was terminated if dilation 
of the culprit lesion was unsuccessful. In patients in Group 
A, prostacyclin (PGI,) was infused immediately after angio- 
plasty into the dilated coronary artery for an additional 15 
min at 7 nglkg per min and, when appropriate, the infusion 
was divided equally among the arteries that were dilated. 
Prostacyclin was then infused intravenously for 48 h at 8.0 
ng/kg per min. Early in the study, the dose was reduced to 
5.0 ng/kg per min because of the high incidence of side 
effects. If nausea occurred during the intravenous infusion, it 
was discontinued for 5 min and resumed at progressively 
lower infusion rates until symptoms abated. Patients in the 
control group received an intracoronary infusion of an 
equivalent volume of diluent over 15 min immediately after 
angioplasty, but did not have diluent administered intrave- 
nously. In addition to prostacyclin or placebo, all patients 
received nifedipine (10 mg) and isosorbide dinitrate (10 mg) 
orally four times daily for 48 h after the procedure. Repeat 
angiography was performed 6 months after angioplasty or 
earlier when dictated by symptoms. 
Data analysis. Angiograms performed at the time of ini- 
tial and follow-up angioplasty were analyzed simultaneously 
by a single angiographer who did not know which patients 
had been treated. Luminal diameter stenosis was measured 
by caliper, comparing the narrowest segment with the prox- 
imal adjacent “normal” segment, and the average of the 
measurements from two or three angiographic views was 
recorded. A single view was used when it was the only one 
in which the stenosis was adequately visualized. Lesion 
length was also measured. Interobserver variability was 
determined by comparison of measurements made by a 
second angiographer, who also did not know the treatment 
group, in 40 randomly selected patients, 20 with restenosis. 
Correlation between measurements by the two observers 
was very good (r = 0.89, SEE = 12%, p < 0.001). All lesions 
compared were classified identically with regard to presence 
or absence of restenosis. 
Angiographic definitions. Two definitions for restenosis 
were prospectively defined: 1) luminal diameter reduction 
~50% in the coronary artery segment previously dilated, and 
2) >50% loss of the immediate gain after angioplasty (23). 
Lesion length was considered to be the length over which the 
luminal diameter was reduced by ~50%. Coronary artery 
dissection was defined as a linear opacification in or adjacent 
to the dilated segment immediately after angioplasty. Suc- 
cessful angioplasty was defined as one in which the luminal 
diameter was increased by 20%, with a final diameter steno- 
sis <50%, provided there was no death, myocardial infarc- 
tion or need for emergency bypass surgery. When dilation of 
only the culprit lesion was successful, the procedure was 
considered successful. Analysis of follow-up angiograms 
was performed only in patients with successfully dilated 
lesions. 
Acute vessel closure was deemed to be present if within 
24 h after successful angioplasty, repeat coronary angiogra- 
phy (performed because of recurrent symptoms or electro- 
cardiographic changes) failed to completely opacify the 
vessel distal to the dilated stenosis. 
Statistical analysis. Two hundred sixty-eight patients 
would be required to demonstrate a 50% reduction in the 
restenosis rate, assuming a restenosis rate of 30% ((u = 0.05, 
p = 0.2) (24). Comparisons between continuous data were 
made using unpaired Student’s t tests, and discrete data 
were assessed with the chi-square statistic. The null hypoth- 
esis was rejected at p < 0.05. All data are presented as mean 
values 2 1 SD. 
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Table 1. Clinical Characteristics in 286 Patients 
Prostacyclin Group Control Group 
(Group A. (Group B, 
n = 139) n = 147) 
Age (yr) 55 2 9 57 + 11 
Male (%) 84 83 
Hypertension (%) 14 38 
Diabetes mellitus (%I 8 15 
Cigarette abuse (%) 50 42 
Serum cholesterol (mmol/liter) 5.34 t 0.88 5.51 t I.1 
Unstable angina (%) 46 56 
Previous MI (%) 42 44 
Ejection fraction 0.66 0.64 
There were no statistically significant differences among these baseline 
variables. MI = myocardial infarction. 
Results 
Patient characteristics (Tables 1 to 3). There were no 
statistically significant differences in baseline characteristics 
between patients who received prostacyclin (Group A) and 
those given placebo (Group B) (Table 1). The angiographic 
findings and data related to the procedures in both groups of 
patients are listed in Table 2. There were no statistically 
significant differences between the groups in any of the 
Table 2. Angiographic and Procedural Data in 286 Patients 
Prostacyclin Group Control Group 
(Group A, (Group B. 
n = 139) n = 147) 
No. of vessels dilated 159 156 
Lesion length (mm) 4.6 +- 2.8 4.8 t 3.1 
Calcification 45% 39% 
Primary success 96% 92% 
Luminal diameter reduction (%) 
Before dilation 80 t II 79 t II 
After dilation 242 11 252 II 
Total occlusion 9 (5%) 7 (4%) 
(before dilation) 
Lesion gradient (mm Hg) 
Before dilation 46* I4 47 + I6 
After dilation 11 +7 11 ?6 
Dissection 36% 34% 
Balloon size (mm) 3.1 t 0.4 3.1 + 0.4 
Maximal balloon pressure (atm) 9.0 + 1.4 9.2 2 1.4 
No. of inflations 
Range l-27 l-22 
Mean 3.9 2 3.9 3.9 ? 3.6 
Total inflation time (s) 145 k 109 146 + 126 
Time intervals (min) 
1st ic infusion to 41 + 35 37 r 28 
balloon inflation 
1st balloon inflation to 40 + 32 34 + 29 
2nd ic infusion 
There were no statistically significant differences among any of the 
variables. ic = intracoronary. 
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observed variables. The distribution of vessels 
each of the patient groups is shown in Table 3. 
693 
dilated in 
Results of angioplasty. Figure 1 illustrates the results in 
all 286 patients enrolled in the study. Angioplasty was 
successful in 134 (96%) of 139 patients who received pros- 
tacyclin (PGI,) (Group A) and 136 (92%:) of 147 control 
patients (Group B) (p = NS). Among the five patients in 
Group A with unsuccessful angioplasty. emergency surgery 
was performed for acute closure in two, the lesion could not 
be crossed in two and an inadequate final angiographic result 
was obtained in one. Among the 11 patients in Group B with 
unsuccessful angioplasty, emergency surgery was performed 
for acute closure in 1, Q wave myocardial infarction oc- 
curred in 3 (including the 1 patient sent for emergency 
surgery and 1 who subsequently died of infarction exten- 
sion). the lesion could not be crossed in 3 and an inadequate 
final angiographic result occurred in 5. 
Follow-up results. Follow-up angiography was performed 
in 125 (93%) of 134 successfully treated patients in Group A 
and 125 (92%) of 136 successfully treated patients in Group 
B. Reasons for not performing follow-up angiography in 
patients in Group A included late bypass surgery in one 
patient. patient refusal in three. late death in one and four 
patients were lost to follow-up study. In Group B, lack of 
follow-up angiography was due to late bypass surgery per- 
formed in one, patient refusal in six. late death in two and 
two patients were lost to follow-up study. 
Incidence of restenosis (Tables 3 and 4). At the time of 
follow-up angiography, restenosis was present in 34 patients 
(27%) in Group A and 40 patients (32%) in Group B (p = 
NS). Similar results were obtained regardless of which 
definition of restenosis was applied. The incidence rate of 
restenosis in each of the vessels dilated is shown in Table 3. 
There was a 9% incidence of restenosis in the left circumflex 
artery in patients in Group A, which was significantly lower 
than that in Group B (39%) (p < 0.05). Restenosis was 
present in 35 (22%) of 159 arteries in patients in Group A and 
in 45 (29%) of 156 arteries in patients in Group B (p = NS). 
The time to follow-up angiography (Tub/e 4). Angiogra- 
phy was performed more commonly in the first 3 months 
after angioplasty (that is, before the end of the scheduled 6 
month follow-up period) because of recurrence of symptoms 
in patients in Group B compared with Group A (12 versus 3, 
p < 0.01). The mean time to follow-up angiography was 
similar in both groups (170 days in Group A versus 141 days 
in Group B, p = NS). 
Qf the 34 patients in Group A with restenosis, 19 (56%) 
had successful repeat angioplasty, 2 (6%) had bypass surgery 
and I3 (38%) had symptoms that were controlled by medical 
therapy alone. Of the 40 patients in Group B with restenosis, 
25 (63%) had repeat angioplasty. 3 (8%) had bypass surgery 
and 12 (30%) received medical therapy. 
Complications (Table 5). Acute vessel closure was seen 
in 4 patients in Group A and 14 patients in Group B (p < 
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Table 3. Incidence of Coronary Restenosis 
Prostacyclin Group Control Group 
All Patients (Group A) (Group B) 
P 
No. Restenosis No. Restenosis No. Restenosis Value 
LAD (total) 160 
Proximal 102 
Diagonal 5 
RI 4 
RCA 17 
LCx (total) 69 
Marginal 12 
Total 315 
44 (28%) 
29 (28%) 
2 (40%) 
0 
19 (24%) 
17 (25%) 
3 (25%) 
70 (22%) 
82 22 (27%) 
58 15 (25%) 
2 I (50%) 
1 0 
41 9 (22%) 
33 3 (9%) 
6 1(17%) 
159 35 (22%) 
78 22 (28%) 
44 14 (32%) 
3 I (33%) 
3 0 
36 10 (28%) 
36 14 (39%) 
6 2 (33%) 
156 45 (29%) 
NS 
NS 
NS 
NS 
NS 
co.05 
NS 
NS 
LAD (total) = native left anterior descending coronary artery (LAD), diagonal branches and ramus intermedius 
(RI); LCx (total) = native left circumflex coronary artery (LCx) and marginal branches; RCA = right coronary artery. 
0.01). Angiographic films obtained immediately after angio- 
plasty and after acute closure were reviewed to determine 
the mechanism of acute closure. The predominant mecha- 
nism was deemed to be thrombosis if an abrupt cutoff was 
seen on the initial angiogram after closure and the lesion 
could be recrossed. Although a contributing role of throm- 
bosis could not be excluded in any case, dissection appeared 
to be the main mechanism in all 4 acute vessel closures in 
Group A and 9 (64%) of the 14 acute closures in Group B. 
Successful reopening was accomplished in 1 of 4 and 12 of 14 
patients in Group A and Group B, respectively. (The specific 
technique used to facilitate successful reopening was not 
documented in each case, but our standard approach during 
that period was prolonged inflations followed by use of a 
larger balloon if stabilization did not result.) 
Ventricular tachycardia or fibrillation did not occur in 
patients who received prostacyclin but occurred in five 
Figure 1. Results in 286 patients enrolled in this study, 139 (Group 
A) receiving prostacyclin and 147 (Group B) receiving placebo. 
PTCA = coronary angioplasty. 
PATIENTS RANWMIZED 
286 
GROUP B 
147 
FAILED PTCA 
SUCCESSFUL PTCA SUCCESSFUL PTCA 
134 136 
NO ANGIOGRAPHIC 
FOLLOWUP 
9 111 _ 
ANGIOGRAPHIC FOLLOWUP ANGIOGRAPHIC FOLLOWUP 
125 125 
RESTENOSIS 
CONTINUED SUCCESS CONTINUED SUCCESS 
91 a5 
patients in the control group (p < 0.05). Q wave myocardial 
infarction occurred in one and three patients in Group A and 
Group B, respectively (p = NS). Emergency bypass surgery 
was performed in two Group A patients and one Group B 
patient. The only procedure-related death occurred in the 
control group. Minor side effects-in particular, nausea and 
vomiting-were common in patients who received prostacy- 
clin, and were the reason for premature drug termination in 
two patients. No patient required transfusion for bleeding 
complications during the course of this study. Hypotension 
occurred more often in patients in Group A (4.8% versus 
0.0% in Group B, p < 0.01); affected patients always 
responded quickly to fluid replacement and did not require 
discontinuation of the drug. 
Discussion 
Does prostacyclin protect against restenosis? The purpose 
of this prospective randomized single-blind study was to 
determine whether short-term prostacyclin (PGI,) adminis- 
tration in addition to aspirin and dipyridamole therapy would 
reduce the incidence of restenosis after angioplasty. The 
principal end point was restenosis demonstrated angiograph- 
ically at 6 months, or earlier when symptoms recurred. 
There was no significant difference in the occurrence of 
restenosis in patients treated with prostacyclin compared 
with those given placebo. The incidence of restenosis in both 
Table 4. Time From Coronary Angioplasty to Angiographic 
Detection of Restenosis 
Time Interval 
0 to 3 months 
3 to 6 months 
6 to 9 months 
>9 months 
Mean (days) 
Prostacyclin Group 
(Group A) 
3 
22 
9 
0 
170 k 61 
Control Group 
(Group B) 
12 
17 
10 
1 
141 ? 88 
p Value 
co.01 
NS 
NS 
NS 
NS 
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Table 5. Complications of Coronary Angioplasty 
Prostacyclin Group Control Group 
(Group A) (Group B) 
No. 1%) No. (%l 
Major 
Acute reclosure 4 (2.9) 14 (9.5) 
Q wave MI 1 (0.8) 3 (2.01 
V tachifib 0 5 (3.4) 
Emergency CABG 2 (I.41 1 (0.7) 
Death 0 1 to.71 
Minor 
Nausea 66 (48) 2 (I.51 
Vomiting 28 (20) I to.71 
Diarrhea 8 (61 0 
Phlebitis 4 (31 0 
Hypotension 6 (4.81 0 
p Value 
co.05 
NS 
co.05 
NS 
NS 
<O.OOl 
<O.OOl 
<0.005 
10.05 
<O.Ol 
CABG = coronary artery bypass grafting; MI = myocardial infarction: V 
tachifib = ventricular tachycardiaifibrillation. 
Group A and Group B (27% and 32%, respectively) was 
similar to that previously reported (l), and the similarity in 
restenosis rate was not altered when analyzed for single and 
multivessel dilation. These findings differ from the prelimi- 
nary report (9) concerning the use of similarly administered 
ciprostene. 
In this study, prostacyclin was initially administered by 
the intracoronary route before and after dilation, and then 
intravenously for 48 h. After endothelial injury, local pro- 
duction of prostacyclin resumes within 48 h and becomes 
normal after several weeks (25). Although it remains possi- 
ble that more prolonged therapy with prostacyclin may 
prevent restenosis, the cost implications of a longer hospital 
stay might make such an approach impractical. 
Although the difference in the incidence of restenosis 
between groups was not statistically significant, it was 
slightly lower in patients given prostacyclin. To establish 
that the observed difference was real would require a study 
of approximately 2,660 patients. The lower incidence of 
restenosis in patients who received prostacyclin and had 
angioplasty in the circumflex coronary artery may be an 
artifact of multiple comparisons because there is no reason 
to expect an artery-selective benefit. 
Acute vessel closure after angioplasty: role of thrombosis 
versus dissection. In the present study, patients who re- 
ceived prostacyclin had a lower incidence of acute closure 
and ventricular arrhythmias. If thrombosis is the common 
denominator in the pathogenesis of these complications 
during angioplasty, our findings are consistent with previous 
reports of a similar benefit observed with antiplatelet agents 
such as aspirin (5), ticlopidine (31), and prostaglandin E, 
(PGE,) (32). The incidence of acute closure in our control 
group was higher than expected from past experience. (Of 
3,400 procedures performed in Calgary, 2.8% have been 
complicated by acute closure.) The reason for this is not 
clear. Although this unexpectedly high rate precludes the 
conclusion that prostacyclin exerted a protective effect 
during coronary angioplasty, there is reason to suspect that 
varying amounts of thrombosis account for the different 
acute closure rates. Angiographic analysis suggested that 
thrombosis was a prominent feature in acute closure in the 
control group but not in the group treated with prostacyclin. 
It is possible that the prolonged intracoronary instrumenta- 
tion needed for placebo infusion without concomitant admin- 
istration of additional antithrombotic agents contributed to 
this increased acute closure rate. 
Mechanisms of restenosis. Although the mean time to Antiarrhythmic effect of prostacyclin. Prevention of acute 
detection of restenosis was similar in both groups of pa- ischemia by an antithrombotic effect may explain the appar- 
tients, fewer patients who were treated with prostacyclin ent antiarrhythmic activity of prostacyclin (33-37). This 
required angiography because of recurrent symptoms within activity is unlikely to be due to the quinidine-like effect of 
3 months of angioplasty. This finding may be explained, at prostacychn because it only occurs at very high concentra- 
least in part, by our current understanding of the mechanism tions of the drug (38). It has been proposed that the balance 
of restenosis (12). The early “deep” injury that is likely to be between thromboxane and prostacyclin release during acute 
responsible for acute vessel closure and early restenosis is ischemia influences electrical stability (39) and that this is 
characterized by atheroma fracture and intraluminal debris, favorably altered by infusion of prostacyclin (40). Further- 
both being potent stimuli to thrombus formation. The “late” more, prostacyclin influences noradrenalin release during 
form, seen with even relatively superficial injury, involves ischemia, reflecting changes in autonomic nervous system 
smooth muscle cell proliferation, which is a complex process activity (41). Finally, because prostacyclin is a peripheral 
mediated in part by growth factors derived from platelets 
and neutrophils. Platelet deposition, important in both early 
and late mechanisms, is also augmented by turbulence and 
increased local shear forces (10). Mechanisms that prevent 
endothelial platelet accumulation in normal coronary arter- 
ies include endothelial production of heparin sulfate (26), 
tissue plasminogen activators (27) and prostacyclin (28). 
Administration of these substances when endothelial pro- 
duction is reduced may limit platelet accumulation during 
angioplasty (29). Prostacyclin administration may also en- 
hance local production of tissue plasminogen activator (30). 
Thus, this preliminary observation suggests that the admin- 
istration of prostacyclin may interfere with early thrombus 
formation even though there is no apparent difference in 
long-term outcome, perhaps because it does not interfere 
with neointimal smooth muscle cell proliferation. Although 
platelet-endothelial interaction may play a role in late reste- 
nosis, long-term aspirin and dipyridamole therapy does not 
appear to influence the process (5). 
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vasodilator, it may reduce ventricular wall stress, thereby 
reducing ventricular irritability (42). 
Conclusions. Short-term administration of intracoronary 
and intravenous prostacyclin (PGI,) did not lead to a signif- 
icant reduction in coronary artery restenosis after angio- 
plasty. Should a larger study confirm that the differences 
noted were real, the extent of this difference and the high 
incidence of minor side effects would not support the routine 
use of prostacyclin. Acute vessel closure and ventricular 
arrhythmias were more common in the control group. De- 
spite the potential role of thrombosis as a cause for these 
complications, this study does not support routine use of 
prostacyclin during angioplasty. 
We gratefully acknowledge the support of the administration and staff of the 
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